Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The name 'Co-biotic' is non-specific and refers to several different products, primarily probiotic dietary supplements, but also a pharmaceutical combination drug and a broader scientific concept. As a dietary supplement, 'Co-biotic' typically refers to products containing one or more strains of beneficial microorganisms, such as Saccharomyces boulardii, Lactobacillus acidophilus, and Lactobacillus bifidus. These supplements are generally used to support intestinal microflora balance, prevent antibiotic-associated diarrhea, and manage conditions like thrush (Candida albicans). The mechanism involves colonizing the intestinal tract, competing with harmful organisms, and modulating the immune response. Some products named 'Co-biotic' are single-strain, while others are multi-strain combinations. Separately, 'Cobiotic LB' is a pharmaceutical drug combining antibiotics (Amoxycillin, Cloxacillin) with Lactobacillus to treat bacterial infections. The term 'co-biotics' also refers to a scientific concept of bioactive compounds that modulate both host and microbiota.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Co-biotic.